Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi).
Delphi procedure
MLD
Metachromatic leukodystrophy
Rare disease registry
Rare diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
14 02 2022
14 02 2022
Historique:
received:
23
11
2021
accepted:
30
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacement therapy, have been developed. Those advances increase the need for high-quality research infrastructure to adequately compare treatments, execute post-marketing surveillance, and perform health technology assessments (HTA). To facilitate this, a group of MLD experts started the MLD initiative (MLDi) and initiated an academia-led European MLD registry: the MLDi. An expert-based consensus procedure, namely a modified Delphi procedure, was used to determine the data elements required to answer academic, regulatory, and HTA research questions. Three distinct sets of data elements were defined by the 13-member expert panel. The minimal set (n = 13) contained demographics and basic disease characteristics. The core set (n = 55) included functional status scores in terms of motor, manual, speech and eating abilities, and causal and supportive treatment characteristics. Health-related quality of life scores were included that were also deemed necessary for HTA. The optional set (n = 31) contained additional clinical aspects, such as findings at neurological examination, detailed motor function, presence of peripheral neuropathy, gall bladder involvement and micturition. Using a modified Delphi procedure with physicians from the main expert centers, consensus was reached on a core set of data that can be collected retrospectively and prospectively. With this consensus-based approach, an important step towards harmonization was made. This unique dataset will support knowledge about the disease and facilitate regulatory requirements related to the launch of new treatments.
Sections du résumé
BACKGROUND
Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacement therapy, have been developed. Those advances increase the need for high-quality research infrastructure to adequately compare treatments, execute post-marketing surveillance, and perform health technology assessments (HTA). To facilitate this, a group of MLD experts started the MLD initiative (MLDi) and initiated an academia-led European MLD registry: the MLDi. An expert-based consensus procedure, namely a modified Delphi procedure, was used to determine the data elements required to answer academic, regulatory, and HTA research questions.
RESULTS
Three distinct sets of data elements were defined by the 13-member expert panel. The minimal set (n = 13) contained demographics and basic disease characteristics. The core set (n = 55) included functional status scores in terms of motor, manual, speech and eating abilities, and causal and supportive treatment characteristics. Health-related quality of life scores were included that were also deemed necessary for HTA. The optional set (n = 31) contained additional clinical aspects, such as findings at neurological examination, detailed motor function, presence of peripheral neuropathy, gall bladder involvement and micturition.
CONCLUSION
Using a modified Delphi procedure with physicians from the main expert centers, consensus was reached on a core set of data that can be collected retrospectively and prospectively. With this consensus-based approach, an important step towards harmonization was made. This unique dataset will support knowledge about the disease and facilitate regulatory requirements related to the launch of new treatments.
Identifiants
pubmed: 35164810
doi: 10.1186/s13023-022-02189-w
pii: 10.1186/s13023-022-02189-w
pmc: PMC8842918
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Orphanet J Rare Dis. 2018 Apr 23;13(1):61
pubmed: 29688860
AJNR Am J Neuroradiol. 2009 Nov;30(10):1893-7
pubmed: 19797797
J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):105-111
pubmed: 28889092
Science. 2013 Aug 23;341(6148):1233158
pubmed: 23845948
Pharmaceut Med. 2020 Jun;34(3):185-190
pubmed: 32215853
J Clin Epidemiol. 2014 Apr;67(4):401-9
pubmed: 24581294
Bone Marrow Transplant. 2013 Mar;48(3):369-75
pubmed: 22941383
Blood. 2016 Jun 16;127(24):3098-101
pubmed: 27118454
Hum Mutat. 2016 Jan;37(1):16-27
pubmed: 26462614
Dev Med Child Neurol. 2019 Feb;61(2):232-235
pubmed: 29806077
JAMA Neurol. 2016 Sep 1;73(9):1133-40
pubmed: 27400410
Expert Rev Pharmacoecon Outcomes Res. 2005 Dec;5(6):705-19
pubmed: 19807613
Dev Med Child Neurol. 2011 Sep;53(9):850-855
pubmed: 21707604
J Child Neurol. 2010 May;25(5):572-80
pubmed: 20038527
Orphanet J Rare Dis. 2021 May 10;16(1):211
pubmed: 33971942
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Neurology. 2010 Nov 23;75(21):1896-903
pubmed: 21098404
Public Health Genomics. 2013;16(6):299-304
pubmed: 24503590
Dev Med Child Neurol. 2011 Feb;53(2):156-60
pubmed: 21087233
Value Health. 2021 Feb;24(2):268-273
pubmed: 33518033
Biol Blood Marrow Transplant. 2013 Apr;19(4):616-24
pubmed: 23348427
Dev Med Child Neurol. 2006 Jul;48(7):549-54
pubmed: 16780622
Food Nutr Bull. 2004 Mar;25(1 Suppl):S37-45
pubmed: 15069918
J Child Neurol. 2016 Nov;31(13):1457-1463
pubmed: 27389394
Ann Clin Transl Neurol. 2015 May;2(5):518-33
pubmed: 26000324
Eur J Hum Genet. 2017 Dec;25(12):1293-1302
pubmed: 29158551
Neurogenetics. 2020 Oct;21(4):289-299
pubmed: 32632536
Iran J Child Neurol. 2015 Summer;9(3):57-61
pubmed: 26401154
Orphanet J Rare Dis. 2018 Sep 5;13(1):154
pubmed: 30185208
Value Health. 2019 Jan;22(1):31-37
pubmed: 30661631
Orphanet J Rare Dis. 2019 Feb 8;14(1):36
pubmed: 30736861
Orphanet J Rare Dis. 2015 Aug 07;10:94
pubmed: 26245762
J Inherit Metab Dis. 2011 Oct;34(5):1095-102
pubmed: 21698385
Med Care. 1999 Feb;37(2):126-39
pubmed: 10024117
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Clin Genet. 2008 Oct;74(4):349-57
pubmed: 18786133
Dev Med Child Neurol. 2018 Feb;60(2):173-184
pubmed: 29171008
Ann Neurol. 2018 Aug;84(2):274-288
pubmed: 30014503
Dev Med Child Neurol. 2014 Mar;56(3):245-51
pubmed: 24344767
Brain. 2021 Aug 16;:
pubmed: 34398223
Pediatr Neurol. 2018 Jul;84:21-26
pubmed: 29859719
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):261-73
pubmed: 25987178
Lancet. 2011 Mar 26;377(9771):1057-9
pubmed: 20674966
Orphanet J Rare Dis. 2019 Jun 11;14(1):136
pubmed: 31186049
Ann Clin Transl Neurol. 2017 May 16;4(6):403-410
pubmed: 28589167
Int Psychogeriatr. 1997;9 Suppl 1:87-94; discussion 143-50
pubmed: 9447431
Source Code Biol Med. 2013 Oct 16;8(1):21
pubmed: 24131574
Public Health Genomics. 2015;18(2):113-22
pubmed: 25677717
Int J Environ Res Public Health. 2018 Aug 03;15(8):
pubmed: 30081484
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
Orphanet J Rare Dis. 2014 Feb 05;9:18
pubmed: 24499656
Ann Clin Transl Neurol. 2015 Sep;2(9):932-40
pubmed: 26401514
Mol Genet Metab. 2020 Sep - Oct;131(1-2):235-244
pubmed: 32792226
Orphanet J Rare Dis. 2020 Sep 3;15(1):235
pubmed: 32883346
Neurology. 2021 Jan 12;96(2):e255-e266
pubmed: 33046606
Qual Life Res. 2010 Aug;19(6):875-86
pubmed: 20405245
J Inherit Metab Dis. 2021 Sep;44(5):1151-1164
pubmed: 33855715
J Pediatr Neurosci. 2019 Apr-Jun;14(2):70-75
pubmed: 31516623
Lancet. 2016 Jul 30;388(10043):476-87
pubmed: 27289174
Drug Saf. 2019 Nov;42(11):1343-1351
pubmed: 31302896
Med Care. 2002 Feb;40(2):113-28
pubmed: 11802084